Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy

Silvia Triarico, Serena Rivetti, Michele Antonio Capozza, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Giorgio Attinà, Antonio Ruggiero

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review


The incidence of PAC is relatively infrequent among pregnant women. However, it has gradually increased in recent years, becoming a challenging area for clinicians that should take into account in the same way maternal benefits and fetal potential risks correlated to the antineoplastic treatment. None of the antineoplastic drugs is completely risk-free during the pregnancy, the timing of exposure and transplacental transfer properties influence the toxicity of the fetus. Despite the lack of guidelines about the management of PAC, several studies have described the use and the potential fetal and neonatal adverse events of antineoplastic drugs during pregnancy. We provide a review of the available literature about the transplacental passage and fetal effects of chemotherapy and targeted agents, to guide the clinicians in the most appropriate choices for the management of PAC.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
Stato di pubblicazionePubblicato - 2022


  • cancer
  • chemotherapy
  • fetus
  • newborn
  • pregnancy
  • targeted agents
  • transplacental passage


Entra nei temi di ricerca di 'Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy'. Insieme formano una fingerprint unica.

Cita questo